Buy Marksans Pharma; target of Rs 385 Choice Institutional Equities

Moneycontrol • 1 day ago

Original source

Key Investment Pillars

  • Marksans Pharma's growth initiatives are translating into financial performance, with the company on track to achieve its target of INR 40 Bn in revenue by FY28E.
  • The US remains a key growth driver, supported by an established customer base and a healthy order book, with the management targeting a USD 300 Mn order book over the next 2-3 years.
  • Europe offers opportunities through geographic expansion and acquisitions, with the Netherlands acquisition providing an immediate revenue base.
  • The Australian business is transitioning towards a branded Rx model, with the management targeting USD 100 Mn in revenue over the next three years.

Thesis Validation Checklist

  • Investors should watch for continued momentum in the US, Europe, and Australia, with a focus on revenue growth, margin expansion, and geographic diversification.
  • The company's ability to achieve its target of INR 40 Bn in revenue by FY28E will be a key indicator of its success.
  • The management's strategy of expanding its branded prescription portfolio and deepening market penetration in Australia will be crucial to the company's long-term growth.
  • Any changes in the regulatory environment or competitive landscape in the US, Europe, or Australia could impact the company's growth prospects.